) -- Biotech stocks continued to march higher at a torrid pace in the first quarter, with the Nasdaq Biotechnology Index (NBI) up 15% compared to a 10% rise in the S&P 500. In fact, the NBI is now comfortably at an all-time high, even higher today that it was during the crazy dot-com and genomics bubble of 1999-2000.
The best way for investors to profit from biotech trading is by staying on top of the most important stock-moving events. To make this job easier, I compiled a list of the most significant biotech trading catalysts for the second quarter. Happy trading!
: Decision on the accelerated approval filing for eteplirsen to treat patients with Duchenne Muscular Dystrophy (exon 51.) Sarepta met with FDA late last month to discuss the eteplirsen filing, so expect a public announcement towards the end of April.
(ZGNX - Get Report)
: FDA approval decision for Zohydro, an extended-release formulation of the chronic pain drug hydrocodone without acetaminophen. A decision could come at any time following a delay of the original March 1 PDUFA date.
(ARNA - Get Report)
: The U.S. commercial launch of the weight-loss pill Belviq in April plus a possible approval decision by European regulators.
: FDA advisory panel reviewing Melblez on May 2. The FDA approval decision is expected on June 14.
: FDA advisory panel reviewing Tivozanib also on May 2.
: FDA decision expected in April on loosening marketing restrictions on the weight-loss pill Qsymia, including allowing the drug to be sold in retail pharmacies.
: FDA approval decision for Probuphine on April 30. Don't be surprised if the decision is delayed three months because Titan and FDA are still working on a final risk management plan.
Hepatitis C drug stocks
: The European Association for the Study of Liver Disease (EASL) will release research abstracts for its closely spring meeting on April 8. [The actual EASL meeting is held April 24-28.] Investor focus will be on new and updated data from
(GILD - Get Report)